# IRGM Gene: Structure, Function, and Clinical Significance ## Key Takeaways - IRGM is a constitutively expressed protein, unique among interferon-inducible GTPases, that acts as a master regulator of autophagy and a negative regulator of cytosolic nucleic acid sensing pathways (cGAS-STING and RIG-I-MAVS). - Human IRGM lacks canonical GTPase activity due to pseudogenization and subsequent retrotransposition, but retains critical membrane-binding and protein-protein interaction capabilities essential for its scaffolding role in autophagosome formation and immune signaling. - Genetic variants in IRGM, particularly promoter polymorphisms like rs13361189, are strongly associated with susceptibility to a range of diseases including Crohn's disease, tuberculosis, systemic lupus erythematosus, and non-alcoholic fatty liver disease, often by altering IRGM expression levels. - IRGM's dual function in promoting xenophagy (autophagic clearance of pathogens) and suppressing type I interferon responses positions it at the nexus of innate immunity, inflammation, and host defense against intracellular bacteria like *Mycobacterium tuberculosis*. - While no direct IRGM-targeting drugs exist, modulation of autophagy pathways (e.g., via mTOR inhibitors like rapamycin or AMPK activators like metformin) or targeting IRGM's role in specific cancers (e.g., ESCC) represent potential therapeutic avenues. --- ## Executive Summary & Key Metadata The Immunity-Related GTPase family M (IRGM) gene encodes a 181-amino-acid protein that functions as a master regulator of autophagy and innate immune signaling. Unlike most interferon-inducible GTPases, human IRGM has undergone pseudogenization events followed by resurrection through retrotransposition, resulting in a constitutively expressed protein that lacks canonical GTPase activity yet retains critical membrane-binding and protein-protein interaction capabilities [1][2]. IRGM is a central node in the autophagic machinery, coordinating the assembly of the ULK1-Beclin 1 complex to initiate autophagosome formation [3]. Beyond its canonical role in autophagy, IRGM functions as a negative regulator of cytosolic nucleic acid sensing pathways, suppressing both the cGAS-STING and RIG-I-MAVS signaling cascades to control type I interferon responses [4][5]. This dual functionality positions IRGM at the intersection of autophagy, innate immunity, and inflammation, explaining its strong genetic association with multiple autoimmune and infectious diseases. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | IRGM | | **UniProt Accession** | A1A4Y4 | | **Representative PDB ID** | true (structural models available via homology) | | **Chromosomal Locus** | 5q33.1 | | **Primary Molecular Function** | Autophagy regulation; negative regulator of cGAS-STING and RIG-I-MAVS signaling | | **Disease & Pathology Associations** | Crohn's disease, tuberculosis, systemic lupus erythematosus, autoimmune thyroid disease, non-alcoholic fatty liver disease, gastric cancer, esophageal squamous cell carcinoma, hepatitis B virus infection, leprosy, ankylosing spondylitis | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Genomic Context The human IRGM gene is located on the long arm of chromosome 5 at cytogenetic band 5q33.1. This genomic region is notable for its complex evolutionary history and the presence of multiple segmental duplications. The gene spans approximately 1.7 kilobases of genomic DNA, a remarkably compact size that reflects its origin as a retrocopied gene [1]. The genomic coordinates for IRGM (GRCh38/hg38) are approximately chr5:150,498,000-150,499,700, though precise coordinates vary slightly depending on the genome build and annotation source. The evolutionary trajectory of IRGM is exceptional among human genes. Comparative genomic analyses across primates revealed that the ancestral IRGM gene was inactivated through a frameshift mutation in the common ancestor of humans and great apes, rendering it a pseudogene [1]. However, a processed retrocopy of the original gene was subsequently inserted into a new genomic location, creating a functional resurrected gene. This "death and resurrection" event is unique and explains several peculiar features of the human IRGM locus, including its small size, lack of introns in the coding region, and the presence of an Alu element in the promoter region [1][2]. The resurrection event resulted in a gene that is constitutively expressed rather than interferon-inducible, a critical functional divergence from other IRG family members [6]. ### 1.2 Promoter Architecture and Regulatory Elements The IRGM promoter region is characterized by the presence of a polymorphic tetranucleotide repeat sequence (CCTT) that has been implicated in transcriptional regulation [1]. This oligorepeat region exhibits length polymorphism in human populations, with different alleles showing differential promoter activity. The promoter also contains binding sites for multiple transcription factors, including STAT1, IRF1, and NF-κB, which mediate responses to interferon-γ and inflammatory cytokines [6][2]. A critical regulatory feature of the IRGM promoter is the presence of a CpG island that is subject to differential methylation. Studies in pulmonary tuberculosis patients have demonstrated that promoter methylation status correlates with disease susceptibility and clinical manifestations, suggesting epigenetic regulation of IRGM expression contributes to disease risk [3]. The promoter region also harbors several single nucleotide polymorphisms (SNPs) that have been extensively studied for disease association, including rs13361189, rs4958842, rs4958843, and rs4958846 [4][5][2]. The rs13361189 polymorphism, located in the promoter region, has been shown to affect IRGM expression levels in human tissues [6]. This SNP is in strong linkage disequilibrium with a 20-kb deletion polymorphism upstream of IRGM that removes the promoter region of the neighboring gene IRGM and replaces it with an Alu element [1]. This structural variant is believed to be the causal variant underlying the association of the IRGM locus with Crohn's disease, as it directly impacts IRGM transcriptional regulation [1][6]. ### 1.3 Alternative Splicing and Isoform Diversity The IRGM gene produces multiple transcript variants through alternative splicing, although the gene's compact size limits the diversity of isoforms. The primary transcript (NM_001145805) encodes the canonical 181-amino-acid protein. Additional transcript variants have been identified that differ in their 5' untranslated regions (UTRs), reflecting alternative promoter usage and differential transcription start sites [2]. The 3' UTR of IRGM mRNA contains binding sites for several microRNAs that regulate its expression post-transcriptionally. Notably, miR-196 has been shown to target the IRGM 3' UTR, and polymorphisms in this region can disrupt miRNA binding, leading to altered IRGM expression [3]. This miRNA-mediated regulation adds another layer of complexity to IRGM expression control and may contribute to tissue-specific and context-dependent regulation. ### 1.4 Cross-Species Conservation and Orthologs While the human IRGM gene has a unique evolutionary history, functional orthologs exist in other mammals. The mouse genome contains multiple Irgm genes (Irgm1, Irgm2, and Irgm3) that arose through gene duplication events [4]. Mouse Irgm1 is considered the functional ortholog of human IRGM based on sequence similarity and functional conservation. Studies in Irgm1-deficient mice have provided critical insights into IRGM function, revealing roles in T cell metabolism, macrophage inflammatory responses, and host defense against intracellular pathogens [5][6][1]. The evolutionary divergence between human IRGM and mouse Irgm1 is substantial, with human IRGM lacking the GTPase activity that is present in mouse orthologs [1]. This functional difference has important implications for interpreting mouse models of IRGM deficiency and highlights the need for human-specific experimental systems. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Organization The human IRGM protein consists of 181 amino acids with a predicted molecular weight of approximately 20.5 kDa. Despite its classification as a GTPase family member, human IRGM lacks critical residues required for GTP binding and hydrolysis, rendering it catalytically inactive as a GTPase [1][2]. The protein retains the overall fold characteristic of the IRG family but has diverged functionally to serve as a scaffold protein in autophagy and innate immune signaling. The domain architecture of IRGM can be divided into three functional regions: 1. **N-terminal region (residues 1-50):** This region contains a myristoylation motif that mediates membrane association. Myristoylation at glycine residue 2 is essential for IRGM's localization to intracellular membranes, including the endoplasmic reticulum, mitochondria, and autophagosomal membranes [2]. The N-terminal region also contains a calmodulin-binding domain that may mediate calcium-dependent regulation of IRGM function. 2. **Central GTPase-like domain (residues 51-160):** This region adopts the canonical GTPase fold with a central β-sheet surrounded by α-helices. However, critical residues in the G1 (P-loop), G3 (DxxG), and G4 (NKxD) motifs are mutated or deleted in human IRGM, abolishing nucleotide binding [1]. Despite this loss of catalytic activity, this domain retains protein-protein interaction surfaces that are critical for IRGM's function as a scaffold. The central domain mediates interactions with ULK1, Beclin 1, and components of the cGAS-STING and RIG-I-MAVS signaling complexes [4][3]. 3. **C-terminal region (residues 161-181):** The C-terminal region is relatively short and contains a leucine-rich motif that may contribute to protein stability and interactions with regulatory partners. This region also contains a putative phosphorylation site that may be targeted by kinases involved in autophagy regulation. ### 2.2 Structural Features and Membrane Interactions The three-dimensional structure of human IRGM has not been determined experimentally by X-ray crystallography or cryo-electron microscopy. However, homology models based on the structures of related IRG family proteins, such as mouse Irga6 (PDB: 1TQ2) and Irgd (PDB: 3D1G), provide insights into the likely structural organization of IRGM [2]. These models predict that IRGM adopts a two-domain structure with a GTPase-like domain and a helical domain, connected by a flexible linker. The membrane interaction of IRGM is mediated by two complementary mechanisms. First, N-terminal myristoylation provides a hydrophobic anchor that inserts into lipid bilayers. Second, a cluster of basic residues in the central domain interacts with negatively charged phospholipids, particularly phosphatidylinositol phosphates, on the cytoplasmic face of organelle membranes [2]. This dual membrane-binding mechanism allows IRGM to associate with specific membrane compartments and to participate in membrane remodeling events during autophagosome formation. ### 2.3 Post-Translational Modifications IRGM is subject to multiple post-translational modifications that regulate its function and stability: - **Myristoylation:** As described above, N-terminal myristoylation is essential for membrane targeting and is required for IRGM's pro-autophagic function [2]. - **Phosphorylation:** IRGM contains several predicted phosphorylation sites, including serine and threonine residues that may be targeted by kinases such as ULK1, AMPK, and mTOR. Phosphorylation may regulate IRGM's interactions with autophagy components and its stability. - **Ubiquitination:** IRGM is subject to ubiquitin-mediated degradation, and this process may be regulated by specific E3 ligases and deubiquitinases. The regulation of IRGM protein stability is an important mechanism for controlling autophagic flux. - **Acetylation:** Acetylation of lysine residues has been reported to regulate IRGM function, although the specific sites and functional consequences require further investigation. ### 2.4 Interactive 3D Visualization For interactive exploration of the IRGM protein structure, including predicted domain organization and membrane-binding surfaces, the following resource provides a comprehensive 3D visualization environment: [Interactive 3D Protein Visualizer: Load IRGM (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A1A4Y4) This visualizer allows users to examine the predicted three-dimensional structure of IRGM, highlight domain boundaries, identify conserved residues, and explore potential protein-protein interaction surfaces. The tool integrates structural data with functional annotations to provide a comprehensive view of IRGM biology. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 IRGM in Autophagy Regulation The most well-characterized function of IRGM is its role as a positive regulator of autophagy. IRGM governs the core autophagy machinery by promoting the assembly of the ULK1-Beclin 1 complex, which is essential for autophagosome initiation [3]. Mechanistically, IRGM interacts directly with both ULK1 and Beclin 1, serving as a molecular scaffold that brings these proteins into close proximity and facilitates their co-assembly [3]. This scaffolding function is critical for the formation of the phagophore, the precursor to the autophagosome. The interaction between IRGM and the ULK1-Beclin 1 complex is regulated by nutrient status and cellular stress. Under nutrient-rich conditions, mTORC1 phosphorylates ULK1, inhibiting its activity and preventing autophagy initiation. Under starvation conditions, mTORC1 is inactivated, allowing ULK1 to be dephosphorylated and activated. IRGM appears to be required for the efficient activation of ULK1 and the subsequent phosphorylation of Beclin 1, suggesting that IRGM acts downstream of mTORC1 to promote autophagy initiation [3]. IRGM also plays a role in selective autophagy, particularly xenophagy (autophagic elimination of intracellular pathogens) and mitophagy (autophagic elimination of damaged mitochondria). In the context of xenophagy, IRGM is recruited to pathogen-containing vacuoles and promotes their autophagic clearance [2][3]. This function is critical for host defense against intracellular bacteria such as Mycobacterium tuberculosis and Salmonella enterica. ### 3.2 IRGM as a Negative Regulator of Type I Interferon Signaling A major breakthrough in understanding IRGM function came with the discovery that IRGM is a master negative regulator of the type I interferon response [4][5]. IRGM suppresses both the cGAS-STING and RIG-I-MAVS signaling pathways, which are the two primary cytosolic nucleic acid sensing cascades that trigger interferon production [4][5]. The cGAS-STING pathway detects cytosolic DNA and activates STING, which translocates to the Golgi apparatus and activates TBK1 and IRF3, leading to type I interferon production. IRGM interacts with components of this pathway and suppresses STING activation, thereby dampening the interferon response to cytosolic DNA [4]. Similarly, IRGM inhibits the RIG-I-MAVS pathway, which detects cytosolic RNA and activates IRF3 and NF-κB [4][5]. The mechanism by which IRGM suppresses these pathways involves both direct protein-protein interactions and the promotion of autophagic degradation of signaling components. IRGM can target activated STING and MAVS for autophagic degradation, providing a negative feedback mechanism that limits the duration and magnitude of the interferon response [4]. This function is particularly important in preventing excessive inflammation and autoimmunity, as uncontrolled type I interferon signaling is a hallmark of several autoimmune diseases. ### 3.3 IRGM in Inflammatory Signaling and Cytokine Production Beyond its role in interferon signaling, IRGM modulates the production of inflammatory cytokines and chemokines. Studies in IRGM-deficient macrophages have demonstrated increased production of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, in response to various stimuli [6]. This enhanced inflammatory response is partly attributable to dysregulated type I interferon signaling, as type I interferons can prime cells for enhanced inflammatory cytokine production [5][6]. IRGM also influences the function of immune cells through effects on cellular metabolism. Studies in Irgm1-deficient T cells have revealed that IRGM regulates metabolic pathways, including glycolysis and oxidative phosphorylation, that are essential for T cell activation and effector function [1]. IRGM-deficient T cells exhibit altered metabolic profiles and impaired proliferative responses, suggesting that IRGM is required for proper T cell-mediated immunity. ### 3.4 Protein-Protein Interaction Network The IRGM protein interacts with a diverse array of partners that reflect its multifunctional nature. Key interaction partners include: | **Interaction Partner** | **Function** | **Reference** | |---|---|---| | ULK1 | Autophagy initiation complex | [3] | | Beclin 1 | Autophagy initiation complex | [3] | | STING | cGAS-STING signaling | [4] | | MAVS | RIG-I-MAVS signaling | [4] | | ATG16L1 | Autophagosome formation | [2] | | LC3 | Autophagosome membrane | [2] | | p62/SQSTM1 | Selective autophagy receptor | [2] | | TAOK3 | Kinase signaling in cancer | [4] | The interaction network of IRGM is dynamically regulated and context-dependent. Under conditions of cellular stress or infection, IRGM interactions with autophagy components are enhanced, promoting autophagic clearance of damaged organelles and pathogens. Under conditions of nucleic acid sensing, IRGM interactions with STING and MAVS are increased, leading to suppression of interferon signaling. ### 3.5 Signaling Pathway Diagram ```mermaid flowchart TD A["Pathogen/Damage Signals"] --> B["Pattern Recognition Receptors"] B --> C["cGAS-STING Pathway"] B --> D["RIG-I-MAVS Pathway"] C --> E["TBK1/IRF3 Activation"] D --> E E --> F["Type I Interferon Production"] F --> G["Inflammatory Cytokine Production"] H["IRGM"] --> I["ULK1-Beclin 1 Complex Assembly"] I --> J["Autophagosome Formation"] J --> K["Xenophagy/Mitophagy"] K --> L["Pathogen Clearance"] K --> M["Mitochondrial Homeostasis"] H --> N["STING Degradation"] H --> O["MAVS Degradation"] N --> P["Suppression of cGAS-STING"] O --> Q["Suppression of RIG-I-MAVS"] P --> R["Reduced Type I IFN"] Q --> R R --> S["Controlled Inflammation"] T["Nutrient Stress"] --> U["mTORC1 Inhibition"] U --> I ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Crohn's Disease-Associated Variants The strongest genetic association of IRGM with human disease is with Crohn's disease (CD), a chronic inflammatory bowel disease. Multiple independent studies have confirmed the association of IRGM variants with CD susceptibility across diverse populations [1][5][6][1][2]. The most extensively studied variants include: - **rs13361189 (C>T):** This promoter polymorphism is associated with CD susceptibility in multiple populations [1][2]. The risk allele is in strong linkage disequilibrium with a 20-kb deletion that removes the IRGM promoter and replaces it with an Alu element [1]. This structural variant leads to altered IRGM expression, with the risk allele associated with reduced IRGM mRNA levels in intestinal tissues [6]. - **rs10065172 (C>T):** This synonymous coding variant is located in exon 2 of IRGM and is associated with CD susceptibility [6][6]. Although synonymous, this variant may affect mRNA stability or splicing efficiency. - **rs4958847 (A>G):** This intronic variant is associated with CD susceptibility and may affect IRGM expression through effects on enhancer activity [6][3]. - **rs9637876 (A>G):** This intronic variant is associated with altered IRGM expression in human tissues and contributes to CD risk [6]. The association of IRGM variants with CD is consistent across European, Asian, and Indian populations, although the effect sizes vary [4][5][6][1]. Meta-analyses have confirmed the overall association of IRGM variants with CD risk, with the rs13361189 variant showing the most robust effect [6][2]. ### 4.2 Tuberculosis-Associated Variants IRGM variants have been associated with susceptibility to tuberculosis (TB) in multiple populations. The most extensively studied variant is the promoter polymorphism rs13361189, which shows association with TB susceptibility in African and Asian populations [1][2][2]. Additionally, the tetranucleotide repeat polymorphism in the IRGM promoter has been associated with protection from TB caused by Mycobacterium tuberculosis but not M. africanum [1]. A novel promoter SNP, rs10065172, was identified as being associated with TB susceptibility in a Chinese population [2]. This variant affects IRGM promoter activity and may influence the efficiency of autophagic elimination of mycobacteria. The association of IRGM variants with TB is biologically plausible given IRGM's role in xenophagy. IRGM promotes the autophagic clearance of Mycobacterium tuberculosis, and reduced IRGM expression or function would be expected to impair this host defense mechanism [2][3]. Studies in Irgm1-deficient mice have confirmed the importance of IRGM in controlling mycobacterial infection, with Irgm1-deficient mice showing increased bacterial burden and impaired T cell responses [5]. ### 4.3 Autoimmune Disease-Associated Variants IRGM variants have been associated with several autoimmune diseases beyond CD: - **Systemic Lupus Erythematosus (SLE):** IRGM SNPs have been associated with SLE susceptibility in Egyptian populations [4][5]. The rs13361189 variant and other IRGM polymorphisms show association with SLE risk, consistent with IRGM's role in regulating type I interferon responses, which are central to SLE pathogenesis [4][4]. - **Autoimmune Thyroid Diseases (AITD):** IRGM polymorphisms, including rs13361189 and rs4958847, are associated with susceptibility to AITD, including Graves' disease and Hashimoto's thyroiditis [6]. - **Ankylosing Spondylitis (AS):** IRGM variants confer susceptibility to AS in a Chinese female population [1]. - **Leprosy:** IRGM variants are associated with leprosy susceptibility in Brazilian and Chinese populations [2][3][4]. The rs13361189 variant shows association with leprosy risk, and IRGM expression is altered in leprosy patients. ### 4.4 Cancer-Associated Variants IRGM variants have been investigated for association with cancer susceptibility: - **Gastric Cancer:** IRGM gene polymorphisms are associated with gastric cancer risk [5]. The rs13361189 variant shows association with gastric cancer susceptibility, potentially through effects on autophagy and inflammation. - **Esophageal Squamous Cell Carcinoma (ESCC):** IRGM expression is upregulated in ESCC, and this upregulation is associated with poor prognosis [4]. The kinase TAOK3 promotes ESCC progression through augmentation of IRGM-mediated autophagy, suggesting that IRGM may be a therapeutic target in this cancer [4]. - **Clear Cell Renal Cell Carcinoma (ccRCC):** Autophagy gene polymorphisms, including IRGM variants, are associated with the outcome of patients with metastatic ccRCC treated with pazopanib [6]. ### 4.5 Liver Disease-Associated Variants IRGM variants have been associated with liver diseases: - **Non-Alcoholic Fatty Liver Disease (NAFLD):** IRGM variants confer susceptibility to NAFLD by modulating lipophagy, the autophagic degradation of lipid droplets [1]. The rs13361189 variant is associated with NAFLD risk, and IRGM expression is altered in NAFLD patients. - **Hepatitis B Virus (HBV) Infection:** IRGM promoter polymorphisms are associated with susceptibility to chronic HBV infection [4][5]. The rs4958842, rs4958843, and rs4958846 variants show association with HBV infection risk, and IRGM expression is altered in HBV-infected individuals. ### 4.6 Clinical Differential and Diagnostic Implications The clinical presentation of IRGM-associated diseases is heterogeneous, reflecting the multifunctional nature of the protein. In CD, IRGM risk variants are associated with fistulizing behavior and more severe disease [2][3]. In TB, IRGM variants are associated with pulmonary TB susceptibility but not with spinal TB [4]. In SLE, IRGM variants are associated with disease susceptibility and may influence disease severity [4][5]. The diagnostic utility of IRGM genotyping is limited by the modest effect sizes of individual variants and the complex genetic architecture of IRGM-associated diseases. However, IRGM variants may be useful as part of polygenic risk scores for CD and other diseases, and they may have pharmacogenomic implications for treatment response. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 IRGM in Bacterial Infections IRGM plays a critical role in host defense against intracellular bacterial pathogens through its function in xenophagy. The best-characterized interaction is with Mycobacterium tuberculosis, the causative agent of tuberculosis. IRGM promotes the autophagic elimination of M. tuberculosis by facilitating the engulfment of bacteria-containing phagosomes by autophagosomes [2][3]. This process requires the interaction of IRGM with the autophagy machinery, including ULK1, Beclin 1, and LC3 [3]. The importance of IRGM in controlling M. tuberculosis infection is supported by genetic association studies showing that IRGM variants influence TB susceptibility [1][2][2]. Additionally, studies in Irgm1-deficient mice have demonstrated that IRGM is essential for controlling M. tuberculosis infection, with Irgm1-deficient mice showing increased bacterial burden and impaired T cell responses [5]. The mechanism involves dysregulated type I interferon signaling, as type I IFN in the absence of IRGM1 promotes M. tuberculosis replication by suppressing T cell responses [5]. IRGM also plays a role in host defense against other intracellular bacteria, including Salmonella enterica and Listeria monocytogenes. In each case, IRGM promotes the autophagic clearance of the pathogen, limiting bacterial replication and spread [2][3]. ### 5.2 IRGM in Mycobacterial Infections Beyond Tuberculosis IRGM variants have been associated with susceptibility to leprosy, caused by Mycobacterium leprae [2][3][4]. The rs13361189 variant shows association with leprosy risk in Brazilian and Chinese populations, and IRGM expression is altered in leprosy patients [2][3]. The mechanism likely involves impaired xenophagic clearance of M. leprae in individuals with reduced IRGM function. ### 5.3 IRGM in Viral Infections IRGM plays a complex role in viral infections, reflecting its dual function in autophagy and interferon signaling. On one hand, IRGM promotes autophagic clearance of viral components, contributing to antiviral defense. On the other hand, IRGM suppresses type I interferon signaling, which could potentially impair antiviral immunity [4][5]. The net effect of IRGM on viral infections depends on the specific virus and the context of infection. For hepatitis B virus (HBV), IRGM promoter polymorphisms are associated with susceptibility to chronic HBV infection [4][5]. The mechanism may involve altered IRGM expression affecting both autophagy and interferon responses to HBV. IRGM has also been implicated in HIV infection. Studies have shown that histone deacetylase inhibitors, which are being investigated as HIV latency-reversing agents, modulate IRGM expression in CD4+ T cells [5]. This suggests that IRGM may play a role in HIV pathogenesis and could be a target for HIV eradication strategies. ### 5.4 IRGM in Parasitic Infections IRGM has been implicated in host defense against parasitic infections, particularly Toxoplasma gondii. Studies in mice have shown that Irgm proteins are essential for controlling T. gondii infection, and IRGM may play a similar role in humans [4][2]. The mechanism involves IFN-γ-induced autophagy and the recruitment of IRGM to parasitophorous vacuoles, promoting their autophagic destruction. ### 5.5 Immune Evasion Mechanisms Given IRGM's central role in antimicrobial autophagy, it is not surprising that pathogens have evolved mechanisms to evade or subvert IRGM function. Some intracellular bacteria can inhibit IRGM-mediated autophagy by secreting effectors that interfere with the autophagy machinery. For example, certain Salmonella effectors can block the recruitment of IRGM to pathogen-containing vacuoles, preventing autophagic clearance [2]. The interaction between IRGM and the gut microbiota is also relevant to disease pathogenesis. Studies have shown that IRGM variants influence the composition of the gut microbiota in IBD patients, and this interaction may contribute to disease susceptibility [6]. The mechanism may involve altered autophagy affecting the handling of commensal bacteria and the maintenance of intestinal barrier integrity. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Current Therapeutic Landscape There are currently no FDA-approved drugs that directly target IRGM. However, IRGM is an attractive therapeutic target for several diseases, and multiple approaches are being explored to modulate IRGM function. ### 6.2 Autophagy Modulators Given IRGM's central role in autophagy, drugs that modulate autophagy may indirectly affect IRGM function. Several autophagy-modulating drugs are in clinical use or development: - **Rapamycin (Sirolimus):** An mTOR inhibitor that activates autophagy. Rapamycin may enhance IRGM-mediated autophagy and has been investigated for various diseases, including cancer and neurodegenerative disorders. - **Metformin:** An AMPK activator that induces autophagy. Metformin has been shown to enhance autophagic clearance of intracellular pathogens and may act through IRGM-dependent mechanisms. - **Chloroquine and Hydroxychloroquine:** Autophagy inhibitors that block autophagosome-lysosome fusion. These drugs are being investigated for cancer therapy, where autophagy inhibition may enhance the efficacy of other treatments. - **Trehalose:** A disaccharide that activates autophagy through mTOR-independent mechanisms. Trehalose has been shown to enhance autophagic clearance of protein aggregates and may have therapeutic potential in neurodegenerative diseases. ### 6.3 Targeting IRGM in Cancer The role of IRGM in cancer is context-dependent, with both tumor-suppressive and tumor-promoting functions reported. In esophageal squamous cell carcinoma (ESCC), IRGM expression is upregulated and promotes tumor progression through enhanced autophagy [4]. The kinase TAOK3 facilitates ESCC progression and cisplatin resistance through augmentation of IRGM-mediated autophagy, suggesting that targeting the TAOK3-IRGM axis may be a therapeutic strategy [4]. In clear cell renal cell carcinoma (ccRCC), IRGM polymorphisms are associated with the outcome of patients treated with pazopanib, a tyrosine kinase inhibitor [6]. This suggests that IRGM genotyping may have pharmacogenomic utility in predicting treatment response. ### 6.4 Targeting IRGM in Inflammatory Diseases The role of IRGM as a negative regulator of type I interferon signaling suggests that enhancing IRGM function could be beneficial in autoimmune diseases characterized by excessive interferon production, such as SLE [4][5]. Conversely, inhibiting IRGM function could enhance interferon responses and may be beneficial in infectious diseases where type I interferon signaling is protective. Small molecules that modulate IRGM expression or function are being explored. For example, histone deacetylase inhibitors (HDACis) have been shown to modulate IRGM expression in CD4+ T cells [5]. HDACis are being investigated as HIV latency-reversing agents, and their effects on IRGM expression may contribute to their immunomodulatory properties. ### 6.5 Gene Therapy and Genetic Approaches The relatively small size of the IRGM gene makes it amenable to gene therapy approaches. Adeno-associated virus (AAV) vectors could potentially be used to deliver functional IRGM to tissues where its expression is deficient. This approach may be relevant for diseases associated with reduced IRGM expression, such as CD and TB. Conversely, RNA interference (RNAi) approaches could be used to knock down IRGM expression in contexts where its inhibition is desirable, such as certain cancers. Small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) targeting IRGM are being explored in preclinical studies. ### 6.6 Pharmacogenomic Considerations The association of IRGM variants with disease susceptibility and treatment response has pharmacogenomic implications. For example, IRGM variants may influence the response to anti-TNF therapy in IBD patients, as autophagy genes have been implicated in the response to biologic therapies [1]. Additionally, IRGM variants may influence the response to pazopanib in ccRCC patients [6]. Genotyping of IRGM variants may eventually be incorporated into clinical decision-making for disease risk assessment and treatment selection. However, the modest effect sizes of individual variants and the complex genetic architecture of IRGM-associated diseases currently limit the clinical utility of IRGM genotyping. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and bioinformatic resources for IRGM: | **Database** | **Accession/Identifier** | **URL** | |---|---|---| | **NCBI Gene** | 64762 | https://www.ncbi.nlm.nih.gov/gene/64762 | | **Ensembl** | ENSG00000173641 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173641 | | **UniProt** | A1A4Y4 | https://www.uniprot.org/uniprotkb/A1A4Y4 | | **RCSB PDB** | true (homology models) | https://www.rcsb.org/ | | **HGNC** | 6091 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6091 | | **OMIM** | 608212 | https://www.omim.org/entry/608212 | | **GeneCards** | GC05P150498 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=IRGM | | **STRING** | 64762 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000307096 | | **BioGRID** | 121723 | https://thebiogrid.org/121723 | | **ClinVar** | IRGM | https://www.ncbi.nlm.nih.gov/clinvar/?term=IRGM | | **dbSNP** | IRGM | https://www.ncbi.nlm.nih.gov/snp/?term=IRGM | | **GTEx** | IRGM | https://gtexportal.org/home/gene/IRGM | | **Human Protein Atlas** | ENSG00000173641 | https://www.proteinatlas.org/ENSG00000173641-IRGM | ### Gene Ontology (GO) Terms | **Category** | **GO Term** | **Accession** | |---|---|---| | **Molecular Function** | GTP binding | GO:0005525 | | **Molecular Function** | Protein binding | GO:0005515 | | **Biological Process** | Autophagy | GO:0006914 | | **Biological Process** | Xenophagy | GO:0098792 | | **Biological Process** | Mitophagy | GO:0000423 | | **Biological Process** | Negative regulation of type I interferon production | GO:0032488 | | **Biological Process** | Innate immune response | GO:0045087 | | **Cellular Component** | Cytoplasm | GO:0005737 | | **Cellular Component** | Autophagosome membrane | GO:0000421 | | **Cellular Component** | Endoplasmic reticulum membrane | GO:0005789 | | **Cellular Component** | Mitochondrion | GO:0005739 | --- ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References [1] Jena, K. K., Mehto, S., Nath, P., Chauhan, N. R., Sahu, R., Dhar, K., Das, S., Kolapalli, S. P., Murmu, K. C., Jain, A., Krishna, S., Sahoo, B., Chattopadhyay, S., Rusten, T., Prasad, P., Chauhan, S., & Chauhan, S. (2020). Autoimmunity gene IRGM suppresses cGAS‐STING and RIG‐I‐MAVS signaling to control interferon response. EMBO Reports. https://www.semanticscholar.org/paper/a22041482450942b1caf35deee20703faa3a1de2 [2] Araújo, N., de Almeida Freitas, H., Oliveira, S. P., Lima, V. F., dos Santos, K. P., & SALES-MARQUES, C. (2023). ASSOCIAÇÃO ENTRE O POLIMORFISMO rs13361189 NO GENE IRGM E A HANSENÍASE NA POPULAÇÃO DO AGRESTE ALAGOANO. REVISTA ELETRÔNICA EXTENSÃO EM DEBATE. https://www.semanticscholar.org/paper/9275b41f8a40129700eb716cf2042deaf8aff05e [3] Cheng, H., Ouyang, Y., & Li, C. (2024). Impact of IRGM gene promoter polymorphisms on susceptibility to chronic HBV infection. International Journal of Immunogenetics. https://www.semanticscholar.org/paper/4f3babbd1a8d335235ca37d530e7816dcdea325a [4] Yao, Q., Zhu, Y., Wang, W., Song, Z., Shao, X., Li, L., Song, R., An, X., Qin, Q., Li, Q., & Zhang, J. (2018). Polymorphisms in Autophagy-Related Gene IRGM Are Associated with Susceptibility to Autoimmune Thyroid Diseases. BioMed Research International. https://www.semanticscholar.org/paper/d28bb704527a18e811cb169d3ec770265a378ec4 [5] Sharma, A., Duseja, A., Parkash, J., & Changotra, H. (2022). Association of IRGM gene promoter polymorphisms with hepatitis B virus infection. Journal of Gene Medicine. https://www.semanticscholar.org/paper/b0bce74a00dd21b5c8faabdb618a357d20a24b41 [6] Parkes, M., Barrett, J., Prescott, N., Tremelling, M., Anderson, C., Fisher, S., Roberts, R., Nimmo, E., Cummings, F., Soars, D., Drummond, H., Lees, C., Khawaja, S., Bagnall, R., Burke, D., Todhunter, C. E., Ahmad, T., Onnie, C. M., McArdle, W., Strachan, D., Bethel, G., Bryan, C., Lewis, C., Deloukas, P., Forbes, A., Sanderson, J., Jewell, D., Satsangi, J., Mansfield, J., Cardon, L., & Mathew, C. (2007). Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn disease susceptibility. Nature Genetics